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Description

Cutaneous malignant melanoma (CMM) is a condition wherein malignant cells form in
the melanocytic cells. CMM is a potentially lethal form of skin cancer, commonly found in
sun-exposed areas of the body. There are multiple risk factors for disease development, such
as genetic mutation and UV radiation among others. Diagnosis and staging is important in
determining disease morbidity and mortality. The United States Preventive Services Task
Force (USPSTF) and the American Academy of Dermatology (AAD) have their respective
guidelines and consensus on diagnosis, staging and treatment. It is imperative to delineate
and educate primary care physicians on CMM, as they serve as the first line of defense in
disease diagnosis. The purpose of this article is to provide a concise educational synopsis for
primary care physicians.
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Introduction

Cutaneous malignant melanoma (CMM) is
a condition wherein malignant cells form in
the melanocytic cells. Melanocytes are found
throughout the lower epidermis and are responsible for producing melanin. CMM is a
potentially lethal form of skin cancer found
most commonly in sun-exposed areas, such as
the face, neck, hands and arms, as seen in other
skin malignancies. Risk factors are multifactorial, including genetic susceptibility and UV
radiation damage.1 Melanoma comprises 2% of
overall skin cancers, with basal and squamous
cell carcinoma compromising the remaining
98%. Non-melanoma skin cancer rarely results
in death or substantial morbidity, whereas
melanoma has notably higher mortality rates.2
In 2020 alone, it is estimated that 100,350 US
men and women would develop melanoma and
6,850 would succumb to the disease.2 Melanoma associated mortality rates are higher
among the middle-aged and elderly. Though

the new cases of melanoma of the skin have
risen over the last 10 years, the overall mortality rate has declined by 7% on an annual basis
between the years of 2013–2017 for both sexes
aged 20–64 years.3 In addition, the mortality
rate has also dramatically declined for individuals 65 years of age and older by 5 to 6% on an
annual basis.3
Prevention is a key criteria of practice for
primary care physicians, and a recent Needs Assessment survey by the American Academy of
Family Physicians (AAFP) in 2019 indicated that
skin cancer management is one of the gaps in
knowledge and practice within this field.4 As
such, it is imperative to delineate and educate
primary care physicians on the latest consensus
on diagnosis and management of CMM, as they
serve as the first line of defense against disease development.4 The purpose of this article
is to provide a concise educational synopsis for
primary care physicians.
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Figure 1. Ugly Duckling Sign, asymmetrical melanoma with uneven color and irregular borders.
Source: Skin Cancer Foundation. Retrieved from NIH National Cancer Institute
https://visualsonline.cancer.gov/details.cfm?imageid=2362.

Incidence and Mortality

There are multiple factors that affect the
incidence of melanoma in the general population. Incidence rates are increased in Caucasian
males, especially those 50 years of age and older. In general, the risk of melanoma increases
with age, fair complexion and exposure to natural or artificial sunlight over prolonged periods
of time.5 Alluding to the multifactorial nature
of the disease, other risk factors include having a family history of melanoma, a dysplastic
nevus, multiple (≥100) nevi and/or having prior
sunburns or diagnosed skin cancers.4 Overall,
5-year survival rates are 91.8% after diagnosis,
with a 5-year survival rate of 98% in individuals
who have localized disease and are diagnosed
earlier. Regional and distant metastatic disease
decreases the overall survival rates to 68% and
16% respectively.1

Diagnosis in the Primary Care
Setting

There remains a lack of consensus among primary care physicians on the benefits of whole
body skin examination. USPSTF states there is
insufficient evidence to assess the balance of
benefits versus harm of visual skin examination by a clinician to screen for skin cancer in
adults.3 In addition, the USPSTF decided not
to continue including a segment about patient
skin self-examinations in their updated recommendation statements. However, the USPSTF
does recommend that children, adolescents
and young adults, ages 10 to 24 years with fair
skin be counseled about minimizing exposure
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to UV radiation in order to reduce their risk of
developing skin cancer.6 The American Academy of Dermatology (AAD) recommends that
individuals with an exponentially increased risk
for melanoma should be checked regularly by
a dermatologist.6 With these disparate recommendations, it falls to the individual physician
to decide who and when to screen by visual
inspection.
Visual inspection remains the first tool in examining patients for possible melanoma. The
clinical visual screening examination assesses
skin lesions using the ABCDE rule.7 This clinical
tool highlights factors that allow for early identification, which is important for eradication.
It includes asymmetry, border, color, diameter
and evolution.5 Symmetry suggests the shape
of one half of a nevus matches the other. Borders should be regular without ragged, notched
or blurred edges. Color should be even and can
be any shade of red, brown or black. A diameter greater than 6 millimeters is concerning. If
the nevus changes over weeks or months, this
change refers to evolution of a nevus. Some
studies show this change to be the most specific finding that may indicate melanoma.7
The ugly duckling sign (Figure 1) is another easy
and simple method for visual identification of
a worrisome nevus. The rule originated since
it was observed that nevi in the same person
tend to resemble one another, and in a group of
nevi, melanoma often strays from the normal
pattern.8 (Figure 2) The ugly duckling sign is
part of a process called differential recognition.
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Figure 2. Normal mole pattern, round with a distinct border. Source: Skin Cancer Foundation.
Retrieved from NIH National Cancer Institute https://visualsonline.cancer.gov/details.cfm?imageid=2359.
Studies show that differential recognition of
the ugly duckling sign was more discriminatory
between CMM than the ABCDE criteria, thus
highlighting the importance of looking for an
outlier in a group of similar nevi.8
Melanoma can have highly specific features
that are visualized using a dermatoscope,
which ultimately leads to a more accurate diagnosis. A dermatoscope is a skin surface microscope that shines polarized light on the skin
and magnifies skin lesions.4 It allows the observer to visualize pigmentation and structures
on the skin surface that are invisible to the unaided eye without obstruction by skin surface
reflections. Interpretation of the structures
follows a 2-step algorithm. First, determine
the melanocytic vs. the non-melanocytic cells.
Then determine the malignant vs. the benign
lesions.5 This algorithm serves as a guide as to
whether to perform a biopsy on the patient,
refer them to a specialist or provide them reassurance. Training in this procedure is important
for success, as lack of familiarity may result in
poorer performance compared with naked eye
examination. There are many online tutorials
and continuing medical education courses for
this training, including an American Academy
of Family Physicians guide that provides images as references for visual structures.4 Benefits of dermoscopy, when used correctly, can
improve diagnostic accuracy from 10 to 27%.4 It
increases the sensitivity and specificity for the
diagnosis of melanoma, is relatively intuitive to
use and aids in direct tissue sampling of large
lesions and those in surgically sensitive areas.

All clinical evaluations of suspicious lesions
should be biopsied. The preferred method is
a narrow excisional/complete elliptical biopsy
with negative margins of (1–3 mm). Full depth
excision is important to prevent transection at
the base.7 This type of excision can be excluded
if the lesion is on the face, in an anatomically
sensitive area or is a large lesion. These areas
of exception can be sampled with punch, deep
shave or partial biopsies. For the importance
of time and efficiency, the most common type
of biopsy done in dermatology and primary
care settings are saucerizations. This type of
biopsy uses a scoop technique that removes
the entire lesion and allows complete sampling
of deep margins. The effectiveness of this
method depends on the comfort and skill of
the physician as well as the clinical situation.7
Biopsy technique must include sample depth
below the plane of the anticipated lesion and
as such, superficial shave biopsies are not indicated. If a melanoma is transected, the staging
tool aspect will be lost. A punch biopsy can be
performed on smaller, pigmented lesions to
remove the entire lesion. For larger lesions or
those in challenging anatomic locations, partial
or sampling with a punch, deep shave or elliptical biopsy can be done.7 The most important
aspect in sampling is to obtain an adequate
specimen to allow for definitive diagnosis. In
addition, it is imperative to obtain pictures of
lesions before and after a biopsy is completed.
When sending the specimen out for pathology,
it is important to document pertinent information for the pathologist. This information
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includes the patient ID, sex and the anatomical
location of the biopsy—including laterality, the
dimension of the lesion and the surgical margins. It is also helpful to include clinical impression, differential diagnosis and lesion size.7 If
macroscopic satellites are observed, this information should be documented as it may play
a role in staging. The method of removal and
the use of hemostatic agents during a biopsy
should be documented. This information serves
as a guide for what margins may be needed if
melanoma is confirmed.7

Disease Staging

Proper staging is based on a combination of
histological and clinical features. Staging is
based on the tumor, nodes and metastasis
(TNM) classification, which is primary tumor
classification, regional lymph nodes and distant metastasis.7 When reviewing the pathology report, histological features of a primary
tumor that are strong predictors of outcome
are Breslow thickness, ulceration and dermal
mitotic rate. Breslow thickness refers to the
maximum tumor thickness from the top of the
granular layer to the deepest layer of malignant
cells. Of these histological features, ulceration
is a negative indicator wherein the tumor
induces full thickness loss of epidermis and
results in dermal changes.7 The biopsy report
should also include the status of microsatellites
as well as peripheral and deep margins. This will
indicate whether the entire lesion was available
and subsequently provides guidance for further
management.7 The patient may have biopsies
to determine primary skin lesions or to confirm
possible metastatic disease that does not have
definitive morphological indicators on routine
stains, thus requiring additional immunohistochemistry analysis in order to confirm the
presence of melanoma.
When completing the initial evaluation of a
patient with newly diagnosed melanoma, it
is important to take time and consideration
for a thorough history and physical exam. The
examiner should include a detailed review of
symptoms by documenting any unanticipated
weight loss, new onset headaches or constitutional symptoms.7 A total skin exam should
be performed. It is also important to evaluate
the primary biopsy site for satellite metastasis
and to evaluate local and distant lymph nodes.
Abnormal laboratory results should also be
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documented. Lactate dehydrogenase (LDH)
levels were added to the staging system for
stage 4 (distant) disease, as high LDH is associated with a worse survival rate and may predict
the response to therapy in stage 4 patients, but
rarely is a sole indicator of metastatic disease.7
The Journal of the American Academy of Dermatology has a grade A recommendation,
which states that at baseline, radiological imaging and lab studies are not recommended for
asymptomatic patients with a newly diagnosed
stage 0–2 primary melanoma.10 They should
only be obtained to evaluate specific signs or
symptoms of metastasis. It is also reported
that a lymph node ultrasound is proven to
be better than palpation alone at the time of
disease diagnosis and follow-up. Furthermore,
routine imaging in patients with an asymptomatic melanoma at any stage is not recommended after 3–5 years of disease-free follow-up.
This recommendation is supported by evidence
that most metastasis occurs in the first 1–3
years after treatment.10

Treatment
Surgical

The primary treatment of a cutaneous malignant melanoma is surgery with a goal of local
control and cure in patients with occult regional or distant metastasis. After the initial biopsy,
a wider and deeper excision is performed to
ensure complete removal of the lesion.7 This
procedure serves to confirm histologically clear
margins and reduce the risk of local recurrence.
Surgical margins differ based on melanoma
staging. A stage T1 melanoma should have a
wide excision allowing a surgical margin of 1
cm. The recommendations for a T2 melanoma,
however, varies from 1–2 cm based on tumor
location as well as functional or cosmetic factors. In areas such as the face, ears, scalp and
fingers—where functional and cosmetic factors
must be taken into consideration—a tissue
sparing excision, such as Mohs micrographic
surgery, should be considered.7
A sentinel lymph node biopsy (SLNB) provides
the most reliable and accurate means of staging for appropriate patients with primary melanoma.7 When indicated, it should be performed
before or concomitantly with a wide excision
of the primary tumor to minimize disruption of
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lymphatic channels and optimize accuracy of
mapping. Discussion of SLNB starts for stage
T1 melanoma depending on other adverse features, and SLNB should be offered for patients
with stage T2.7

Non-surgical

In older individuals who may be poor surgical
candidates, topical imiquimod 5% cream has
been studied as a potential therapy. However,
in the primary treatment setting, there is a risk
of undertreating with imiquimod alone. When
combined with topical tazarotene 0.1%, a complete response was observed histologically in a
12-week treatment period in 78% of patients,
whereas only 64% of patients achieved complete response when treated with imiquimod
alone for the same length of time.7 In addition
to combination therapy, an important factor in
the eradication of the cancer is the duration of
treatment until a clinical and pathologic response is achieved.7
Radiation therapy for non-surgical candidates
may be used as second line, though the practice is uncommon in the United States.9 Adequacy of dermal penetration is a concern with
low voltage radiation. Investigators suggest
that a penetration depth of 5 mm is needed in
order to receive radiation treatment. However,
that depth may result in permanent pigment
changes, dermal fibrosis and overlying hair
loss.9 Adjuvant radiation therapy is associated
with improved local control for desmoplastic
melanoma, though there is no observed effect
on metastasis-free survival. A consult with a
radiation oncologist is encouraged to discuss
risks and benefits of radiation therapy.5

Special Consideration

Pregnancy and cutaneous malignant
melanoma

In some studies, CMM is the most commonly
reported malignancy during pregnancy. CMM
rates are higher in men than women, but when
it does present in women, CMM is usually
more prevalent during reproductive years.10
Evidence is lacking on whether nevi darken or
enlarge during pregnancy, except for those on
the breast and abdomen, which may appear
larger due to stretching. In pregnant women, a
tailored multidisciplinary approach is required,
involving the obstetrician, dermatologist, mela-

noma specialist and medical oncologist.10
Diagnosis of melanoma during pregnancy does
not change the prognosis for women. In women with a history of melanoma, a prolonged
waiting period before the subsequent pregnancy is not recommended.10 Factors that detect
disease recurrence include melanoma thickness, stage, advanced age and fertility level.
The approach to a melanocytic nevus should
be the same as in a non-pregnant patient. In
treatment, exogenous hormones may be used
in women diagnosed with this disease.10

Surveillance and Follow-Up Care

Annual skin examinations are recommended for
life and regular clinical follow-up is the most
important means of detecting recurrence.
Serum S-100B protein is a potential prognostic
biomarker and is a useful tool to identify disease progression.10 Patients should be educated
on regular skin self-exams for early detection
of recurrent or new disease. A grade C recommendation from the AAD states that for high
risk melanoma and +SLNB requires collaboration with medical oncology for multidisciplinary
care.10
A dermatological assessment should be done
for patients with melanoma who are undergoing BRAFI-kinase specific treatment or other
targeted therapies with immune checkpoint
inhibitors.10 The spectrum of melanoma tumor subtypes is rapidly expanding, including
mutations in CDKN2A, CDK4, TERT, BRACA1
and BAP1 cell lines.10 It is imperative to look for
familial lineage with early onset of disease less
than or equal to 40 years of age, multiple cancers or cancer types, multigenerational involvement, aggregation or rare cancers. Genetic
counseling should be recommended in patients
with melanoma that have a family history of
invasive disease, pancreatic cancer (3 or more
on one side of the family) and multiple primary
invasive melanomas (3 or more), early age of
tumor onset less than or equal to 45 years of
age in conjunction with a family member with
mesothelioma, meningioma or uveal melanoma. The role of genomic profiling remains an
active area of exploration.10
The 2019 review from the AAD on CMM has
additional guidance, which has been included
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since 2011, such as further randomized control
trials (RCTs), case reports and, more importantly, novel therapeutic agents approved by
the Food and Drug Administration (FDA) for
advanced or surgically inoperable melanoma.10
These novel therapeutic agents include immune
checkpoint inhibitors, such as ipilimumab and
pembrolizumab. Hence, the new update on
CMM recognizes the importance of determining side effects of these medications, which is
critical for dermatologists and other specialties to recognize.10 However, some of the key
aspects of CMM recognition, diagnosis and
management are still under continuous review
and investigation, such as noninvasive biopsy
techniques using a high-frequency ultrasound
and optical coherence tomography among others. The 2019 update also highlights the need
for further research in CMM, including treatment (surgical vs. nonsurgical), appropriate
margin control definitions, prognostic biomarkers and the utilization of genomic medicine in
genetic counseling of high risk patients. Thus,
the overall take home message is the multifactorial nature of this disease and the requisition
for a personalized approach to management
for each patient.10
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